Global Spine Biologics

Spine Biologics Comprehensive Study by Type (Bone Graft Substitutes (Synthetic Bone Grafts, Demineralized Bone Matrix (DBM), Bone Morphogenetic Proteins (BMP)), Bone Allografts (Machined Bone Allograft, Demineralized Bone Matrix), Platelet Rich Plasma (PRP), Bone Marrow Aspirate Concentrate (BMAC) Therapy), Application (Hospitals, Orthopedic Clinics, Ambulatory Surgical Centers, Others), Surgery Type (Anterior Cervical Discectomy and Fusion (ACDF), Transforamenal Lumbar Interbody Fusion (TLIF), Anterior Lumbar Interbody Fusion (ALIF), Lateral Lumbar Interbody Fusion (LLIF)) Players and Region - Global Market Outlook to 2026

Spine Biologics Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Spine Biologics Market Scope?
Spinal biologics include materials that can be used in bone fusion surgery, spinal cord injuries, and degenerative disc disease. Ten years ago, the spine treatment market was 75% traditional metal rods and plates and 25% biologics. However, because metals are inert materials, they did not stimulate the bone regeneration process. On the other hand, biological materials are proteins that can attract and stimulate cells, promote fusion, and aid the bone healing process. Surgeons use advanced biological mechanisms to treat spinal deformities such as extreme lateral interbody fusion and direct lateral interbody fusion. According to a research article published in BMC Musculoskeletal Disorders in 2018, the study concluded that the minimally invasive approach of lateral interbody fusion technology has the benefit of reduced injury and quick recovery after surgery. This is an effective and safe treatment for spinal diseases such as thoracic and lumbar tuberculosis. Advances in biomaterials are making it easier for surgeons to treat people with spinal conditions such as disc degeneration and scoliosis.

The Spine Biologics market study is being classified by Type (Bone Graft Substitutes [Synthetic Bone Grafts, Demineralized Bone Matrix (DBM), Bone Morphogenetic Proteins (BMP)], Bone Allografts [Machined Bone Allograft, Demineralized Bone Matrix], Platelet Rich Plasma (PRP) and Bone Marrow Aspirate Concentrate (BMAC) Therapy), by Application (Hospitals, Orthopedic Clinics, Ambulatory Surgical Centers and Others) and major geographies with country level break-up.

The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analysts at AMA predicts that Players from United States will contribute to the maximum growth of Global Spine Biologics market throughout the predicted period.

Zimmer Holding (United States), Medical Devices Business Services, Inc. (United States), Medtronic (Ireland), NuVasive, Inc. (United States), Stryker Corporation (United States), Orthofix International (United States), Globus Medical (United States), Exactech, Inc. (United States), Wright Medical Group N.V. (United States), NuTech (United States) and Arthrex, Inc. (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are XTANT MEDICAL (United States), ATEC Spine, Inc. (United States) and Life Spine, Inc. (United States).

Segmentation Analysis
Analyst at AMA have segmented the market study of Global Spine Biologics market by Type, Application and Region.

On the basis of geography, the market of Spine Biologics has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

In 2018, NuVasive had expanded its biologics business line with the launch of AttraX Scaffold.


Influencing Market Trend
  • Awareness of the Newly Developed Spine Treatment Techniques and Devices
  • Rising Demand of Minimally Invasive Spine Surgeries

Market Drivers
  • Rising Incidence of Spinal Disorders
  • Rising Healthcare Expenditure in Developing Nations Owing To Growing Income Levels
  • Rising Obesity Cases

Opportunities
  • An Upsurge in Technological Advancements
  • Growing Health Care Expenditure

Restraints
  • Lack of Expertise and Professionals
  • High Cost of Surgery

Challenges
  • Lack of Patient Awareness
  • Unfavorable Reimbursement Scenario


Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Providers of Spine Biologics, Venture Capitalists and Private Equity Firms and End-Use Industry

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.

To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research features not just specific market sizing estimates, but also include significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets , To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.

Report Objectives / Segmentation Covered

By Type
  • Bone Graft Substitutes [Synthetic Bone Grafts, Demineralized Bone Matrix (DBM), Bone Morphogenetic Proteins (BMP)]
  • Bone Allografts [Machined Bone Allograft, Demineralized Bone Matrix]
  • Platelet Rich Plasma (PRP)
  • Bone Marrow Aspirate Concentrate (BMAC) Therapy
By Application
  • Hospitals
  • Orthopedic Clinics
  • Ambulatory Surgical Centers
  • Others
By Surgery Type
  • Anterior Cervical Discectomy and Fusion (ACDF)
  • Transforamenal Lumbar Interbody Fusion (TLIF)
  • Anterior Lumbar Interbody Fusion (ALIF)
  • Lateral Lumbar Interbody Fusion (LLIF)

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Incidence of Spinal Disorders
      • 3.2.2. Rising Healthcare Expenditure in Developing Nations Owing To Growing Income Levels
      • 3.2.3. Rising Obesity Cases
    • 3.3. Market Challenges
      • 3.3.1. Lack of Patient Awareness
      • 3.3.2. Unfavorable Reimbursement Scenario
    • 3.4. Market Trends
      • 3.4.1. Awareness of the Newly Developed Spine Treatment Techniques and Devices
      • 3.4.2. Rising Demand of Minimally Invasive Spine Surgeries
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Spine Biologics, by Type, Application, Surgery Type and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Spine Biologics (Value)
      • 5.2.1. Global Spine Biologics by: Type (Value)
        • 5.2.1.1. Bone Graft Substitutes [Synthetic Bone Grafts, Demineralized Bone Matrix (DBM), Bone Morphogenetic Proteins (BMP)]
        • 5.2.1.2. Bone Allografts [Machined Bone Allograft, Demineralized Bone Matrix]
        • 5.2.1.3. Platelet Rich Plasma (PRP)
        • 5.2.1.4. Bone Marrow Aspirate Concentrate (BMAC) Therapy
      • 5.2.2. Global Spine Biologics by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Orthopedic Clinics
        • 5.2.2.3. Ambulatory Surgical Centers
        • 5.2.2.4. Others
      • 5.2.3. Global Spine Biologics by: Surgery Type (Value)
        • 5.2.3.1. Anterior Cervical Discectomy and Fusion (ACDF)
        • 5.2.3.2. Transforamenal Lumbar Interbody Fusion (TLIF)
        • 5.2.3.3. Anterior Lumbar Interbody Fusion (ALIF)
        • 5.2.3.4. Lateral Lumbar Interbody Fusion (LLIF)
      • 5.2.4. Global Spine Biologics Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Spine Biologics (Price)
      • 5.3.1. Global Spine Biologics by: Type (Price)
  • 6. Spine Biologics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Zimmer Holding (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Medical Devices Business Services, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Medtronic (Ireland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. NuVasive, Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Stryker Corporation (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Orthofix International (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Globus Medical (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Exactech, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Wright Medical Group N.V. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. NuTech (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Arthrex, Inc. (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Spine Biologics Sale, by Type, Application, Surgery Type and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Spine Biologics (Value)
      • 7.2.1. Global Spine Biologics by: Type (Value)
        • 7.2.1.1. Bone Graft Substitutes [Synthetic Bone Grafts, Demineralized Bone Matrix (DBM), Bone Morphogenetic Proteins (BMP)]
        • 7.2.1.2. Bone Allografts [Machined Bone Allograft, Demineralized Bone Matrix]
        • 7.2.1.3. Platelet Rich Plasma (PRP)
        • 7.2.1.4. Bone Marrow Aspirate Concentrate (BMAC) Therapy
      • 7.2.2. Global Spine Biologics by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Orthopedic Clinics
        • 7.2.2.3. Ambulatory Surgical Centers
        • 7.2.2.4. Others
      • 7.2.3. Global Spine Biologics by: Surgery Type (Value)
        • 7.2.3.1. Anterior Cervical Discectomy and Fusion (ACDF)
        • 7.2.3.2. Transforamenal Lumbar Interbody Fusion (TLIF)
        • 7.2.3.3. Anterior Lumbar Interbody Fusion (ALIF)
        • 7.2.3.4. Lateral Lumbar Interbody Fusion (LLIF)
      • 7.2.4. Global Spine Biologics Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Spine Biologics (Price)
      • 7.3.1. Global Spine Biologics by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Spine Biologics: by Type(USD Million)
  • Table 2. Spine Biologics Bone Graft Substitutes [Synthetic Bone Grafts, Demineralized Bone Matrix (DBM), Bone Morphogenetic Proteins (BMP)] , by Region USD Million (2015-2020)
  • Table 3. Spine Biologics Bone Allografts [Machined Bone Allograft, Demineralized Bone Matrix] , by Region USD Million (2015-2020)
  • Table 4. Spine Biologics Platelet Rich Plasma (PRP) , by Region USD Million (2015-2020)
  • Table 5. Spine Biologics Bone Marrow Aspirate Concentrate (BMAC) Therapy , by Region USD Million (2015-2020)
  • Table 6. Spine Biologics: by Application(USD Million)
  • Table 7. Spine Biologics Hospitals , by Region USD Million (2015-2020)
  • Table 8. Spine Biologics Orthopedic Clinics , by Region USD Million (2015-2020)
  • Table 9. Spine Biologics Ambulatory Surgical Centers , by Region USD Million (2015-2020)
  • Table 10. Spine Biologics Others , by Region USD Million (2015-2020)
  • Table 11. Spine Biologics: by Surgery Type(USD Million)
  • Table 12. Spine Biologics Anterior Cervical Discectomy and Fusion (ACDF) , by Region USD Million (2015-2020)
  • Table 13. Spine Biologics Transforamenal Lumbar Interbody Fusion (TLIF) , by Region USD Million (2015-2020)
  • Table 14. Spine Biologics Anterior Lumbar Interbody Fusion (ALIF) , by Region USD Million (2015-2020)
  • Table 15. Spine Biologics Lateral Lumbar Interbody Fusion (LLIF) , by Region USD Million (2015-2020)
  • Table 16. South America Spine Biologics, by Country USD Million (2015-2020)
  • Table 17. South America Spine Biologics, by Type USD Million (2015-2020)
  • Table 18. South America Spine Biologics, by Application USD Million (2015-2020)
  • Table 19. South America Spine Biologics, by Surgery Type USD Million (2015-2020)
  • Table 20. Brazil Spine Biologics, by Type USD Million (2015-2020)
  • Table 21. Brazil Spine Biologics, by Application USD Million (2015-2020)
  • Table 22. Brazil Spine Biologics, by Surgery Type USD Million (2015-2020)
  • Table 23. Argentina Spine Biologics, by Type USD Million (2015-2020)
  • Table 24. Argentina Spine Biologics, by Application USD Million (2015-2020)
  • Table 25. Argentina Spine Biologics, by Surgery Type USD Million (2015-2020)
  • Table 26. Rest of South America Spine Biologics, by Type USD Million (2015-2020)
  • Table 27. Rest of South America Spine Biologics, by Application USD Million (2015-2020)
  • Table 28. Rest of South America Spine Biologics, by Surgery Type USD Million (2015-2020)
  • Table 29. Asia Pacific Spine Biologics, by Country USD Million (2015-2020)
  • Table 30. Asia Pacific Spine Biologics, by Type USD Million (2015-2020)
  • Table 31. Asia Pacific Spine Biologics, by Application USD Million (2015-2020)
  • Table 32. Asia Pacific Spine Biologics, by Surgery Type USD Million (2015-2020)
  • Table 33. China Spine Biologics, by Type USD Million (2015-2020)
  • Table 34. China Spine Biologics, by Application USD Million (2015-2020)
  • Table 35. China Spine Biologics, by Surgery Type USD Million (2015-2020)
  • Table 36. Japan Spine Biologics, by Type USD Million (2015-2020)
  • Table 37. Japan Spine Biologics, by Application USD Million (2015-2020)
  • Table 38. Japan Spine Biologics, by Surgery Type USD Million (2015-2020)
  • Table 39. India Spine Biologics, by Type USD Million (2015-2020)
  • Table 40. India Spine Biologics, by Application USD Million (2015-2020)
  • Table 41. India Spine Biologics, by Surgery Type USD Million (2015-2020)
  • Table 42. South Korea Spine Biologics, by Type USD Million (2015-2020)
  • Table 43. South Korea Spine Biologics, by Application USD Million (2015-2020)
  • Table 44. South Korea Spine Biologics, by Surgery Type USD Million (2015-2020)
  • Table 45. Taiwan Spine Biologics, by Type USD Million (2015-2020)
  • Table 46. Taiwan Spine Biologics, by Application USD Million (2015-2020)
  • Table 47. Taiwan Spine Biologics, by Surgery Type USD Million (2015-2020)
  • Table 48. Australia Spine Biologics, by Type USD Million (2015-2020)
  • Table 49. Australia Spine Biologics, by Application USD Million (2015-2020)
  • Table 50. Australia Spine Biologics, by Surgery Type USD Million (2015-2020)
  • Table 51. Rest of Asia-Pacific Spine Biologics, by Type USD Million (2015-2020)
  • Table 52. Rest of Asia-Pacific Spine Biologics, by Application USD Million (2015-2020)
  • Table 53. Rest of Asia-Pacific Spine Biologics, by Surgery Type USD Million (2015-2020)
  • Table 54. Europe Spine Biologics, by Country USD Million (2015-2020)
  • Table 55. Europe Spine Biologics, by Type USD Million (2015-2020)
  • Table 56. Europe Spine Biologics, by Application USD Million (2015-2020)
  • Table 57. Europe Spine Biologics, by Surgery Type USD Million (2015-2020)
  • Table 58. Germany Spine Biologics, by Type USD Million (2015-2020)
  • Table 59. Germany Spine Biologics, by Application USD Million (2015-2020)
  • Table 60. Germany Spine Biologics, by Surgery Type USD Million (2015-2020)
  • Table 61. France Spine Biologics, by Type USD Million (2015-2020)
  • Table 62. France Spine Biologics, by Application USD Million (2015-2020)
  • Table 63. France Spine Biologics, by Surgery Type USD Million (2015-2020)
  • Table 64. Italy Spine Biologics, by Type USD Million (2015-2020)
  • Table 65. Italy Spine Biologics, by Application USD Million (2015-2020)
  • Table 66. Italy Spine Biologics, by Surgery Type USD Million (2015-2020)
  • Table 67. United Kingdom Spine Biologics, by Type USD Million (2015-2020)
  • Table 68. United Kingdom Spine Biologics, by Application USD Million (2015-2020)
  • Table 69. United Kingdom Spine Biologics, by Surgery Type USD Million (2015-2020)
  • Table 70. Netherlands Spine Biologics, by Type USD Million (2015-2020)
  • Table 71. Netherlands Spine Biologics, by Application USD Million (2015-2020)
  • Table 72. Netherlands Spine Biologics, by Surgery Type USD Million (2015-2020)
  • Table 73. Rest of Europe Spine Biologics, by Type USD Million (2015-2020)
  • Table 74. Rest of Europe Spine Biologics, by Application USD Million (2015-2020)
  • Table 75. Rest of Europe Spine Biologics, by Surgery Type USD Million (2015-2020)
  • Table 76. MEA Spine Biologics, by Country USD Million (2015-2020)
  • Table 77. MEA Spine Biologics, by Type USD Million (2015-2020)
  • Table 78. MEA Spine Biologics, by Application USD Million (2015-2020)
  • Table 79. MEA Spine Biologics, by Surgery Type USD Million (2015-2020)
  • Table 80. Middle East Spine Biologics, by Type USD Million (2015-2020)
  • Table 81. Middle East Spine Biologics, by Application USD Million (2015-2020)
  • Table 82. Middle East Spine Biologics, by Surgery Type USD Million (2015-2020)
  • Table 83. Africa Spine Biologics, by Type USD Million (2015-2020)
  • Table 84. Africa Spine Biologics, by Application USD Million (2015-2020)
  • Table 85. Africa Spine Biologics, by Surgery Type USD Million (2015-2020)
  • Table 86. North America Spine Biologics, by Country USD Million (2015-2020)
  • Table 87. North America Spine Biologics, by Type USD Million (2015-2020)
  • Table 88. North America Spine Biologics, by Application USD Million (2015-2020)
  • Table 89. North America Spine Biologics, by Surgery Type USD Million (2015-2020)
  • Table 90. United States Spine Biologics, by Type USD Million (2015-2020)
  • Table 91. United States Spine Biologics, by Application USD Million (2015-2020)
  • Table 92. United States Spine Biologics, by Surgery Type USD Million (2015-2020)
  • Table 93. Canada Spine Biologics, by Type USD Million (2015-2020)
  • Table 94. Canada Spine Biologics, by Application USD Million (2015-2020)
  • Table 95. Canada Spine Biologics, by Surgery Type USD Million (2015-2020)
  • Table 96. Mexico Spine Biologics, by Type USD Million (2015-2020)
  • Table 97. Mexico Spine Biologics, by Application USD Million (2015-2020)
  • Table 98. Mexico Spine Biologics, by Surgery Type USD Million (2015-2020)
  • Table 99. Spine Biologics: by Type(USD/Units)
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Spine Biologics: by Type(USD Million)
  • Table 112. Spine Biologics Bone Graft Substitutes [Synthetic Bone Grafts, Demineralized Bone Matrix (DBM), Bone Morphogenetic Proteins (BMP)] , by Region USD Million (2021-2026)
  • Table 113. Spine Biologics Bone Allografts [Machined Bone Allograft, Demineralized Bone Matrix] , by Region USD Million (2021-2026)
  • Table 114. Spine Biologics Platelet Rich Plasma (PRP) , by Region USD Million (2021-2026)
  • Table 115. Spine Biologics Bone Marrow Aspirate Concentrate (BMAC) Therapy , by Region USD Million (2021-2026)
  • Table 116. Spine Biologics: by Application(USD Million)
  • Table 117. Spine Biologics Hospitals , by Region USD Million (2021-2026)
  • Table 118. Spine Biologics Orthopedic Clinics , by Region USD Million (2021-2026)
  • Table 119. Spine Biologics Ambulatory Surgical Centers , by Region USD Million (2021-2026)
  • Table 120. Spine Biologics Others , by Region USD Million (2021-2026)
  • Table 121. Spine Biologics: by Surgery Type(USD Million)
  • Table 122. Spine Biologics Anterior Cervical Discectomy and Fusion (ACDF) , by Region USD Million (2021-2026)
  • Table 123. Spine Biologics Transforamenal Lumbar Interbody Fusion (TLIF) , by Region USD Million (2021-2026)
  • Table 124. Spine Biologics Anterior Lumbar Interbody Fusion (ALIF) , by Region USD Million (2021-2026)
  • Table 125. Spine Biologics Lateral Lumbar Interbody Fusion (LLIF) , by Region USD Million (2021-2026)
  • Table 126. South America Spine Biologics, by Country USD Million (2021-2026)
  • Table 127. South America Spine Biologics, by Type USD Million (2021-2026)
  • Table 128. South America Spine Biologics, by Application USD Million (2021-2026)
  • Table 129. South America Spine Biologics, by Surgery Type USD Million (2021-2026)
  • Table 130. Brazil Spine Biologics, by Type USD Million (2021-2026)
  • Table 131. Brazil Spine Biologics, by Application USD Million (2021-2026)
  • Table 132. Brazil Spine Biologics, by Surgery Type USD Million (2021-2026)
  • Table 133. Argentina Spine Biologics, by Type USD Million (2021-2026)
  • Table 134. Argentina Spine Biologics, by Application USD Million (2021-2026)
  • Table 135. Argentina Spine Biologics, by Surgery Type USD Million (2021-2026)
  • Table 136. Rest of South America Spine Biologics, by Type USD Million (2021-2026)
  • Table 137. Rest of South America Spine Biologics, by Application USD Million (2021-2026)
  • Table 138. Rest of South America Spine Biologics, by Surgery Type USD Million (2021-2026)
  • Table 139. Asia Pacific Spine Biologics, by Country USD Million (2021-2026)
  • Table 140. Asia Pacific Spine Biologics, by Type USD Million (2021-2026)
  • Table 141. Asia Pacific Spine Biologics, by Application USD Million (2021-2026)
  • Table 142. Asia Pacific Spine Biologics, by Surgery Type USD Million (2021-2026)
  • Table 143. China Spine Biologics, by Type USD Million (2021-2026)
  • Table 144. China Spine Biologics, by Application USD Million (2021-2026)
  • Table 145. China Spine Biologics, by Surgery Type USD Million (2021-2026)
  • Table 146. Japan Spine Biologics, by Type USD Million (2021-2026)
  • Table 147. Japan Spine Biologics, by Application USD Million (2021-2026)
  • Table 148. Japan Spine Biologics, by Surgery Type USD Million (2021-2026)
  • Table 149. India Spine Biologics, by Type USD Million (2021-2026)
  • Table 150. India Spine Biologics, by Application USD Million (2021-2026)
  • Table 151. India Spine Biologics, by Surgery Type USD Million (2021-2026)
  • Table 152. South Korea Spine Biologics, by Type USD Million (2021-2026)
  • Table 153. South Korea Spine Biologics, by Application USD Million (2021-2026)
  • Table 154. South Korea Spine Biologics, by Surgery Type USD Million (2021-2026)
  • Table 155. Taiwan Spine Biologics, by Type USD Million (2021-2026)
  • Table 156. Taiwan Spine Biologics, by Application USD Million (2021-2026)
  • Table 157. Taiwan Spine Biologics, by Surgery Type USD Million (2021-2026)
  • Table 158. Australia Spine Biologics, by Type USD Million (2021-2026)
  • Table 159. Australia Spine Biologics, by Application USD Million (2021-2026)
  • Table 160. Australia Spine Biologics, by Surgery Type USD Million (2021-2026)
  • Table 161. Rest of Asia-Pacific Spine Biologics, by Type USD Million (2021-2026)
  • Table 162. Rest of Asia-Pacific Spine Biologics, by Application USD Million (2021-2026)
  • Table 163. Rest of Asia-Pacific Spine Biologics, by Surgery Type USD Million (2021-2026)
  • Table 164. Europe Spine Biologics, by Country USD Million (2021-2026)
  • Table 165. Europe Spine Biologics, by Type USD Million (2021-2026)
  • Table 166. Europe Spine Biologics, by Application USD Million (2021-2026)
  • Table 167. Europe Spine Biologics, by Surgery Type USD Million (2021-2026)
  • Table 168. Germany Spine Biologics, by Type USD Million (2021-2026)
  • Table 169. Germany Spine Biologics, by Application USD Million (2021-2026)
  • Table 170. Germany Spine Biologics, by Surgery Type USD Million (2021-2026)
  • Table 171. France Spine Biologics, by Type USD Million (2021-2026)
  • Table 172. France Spine Biologics, by Application USD Million (2021-2026)
  • Table 173. France Spine Biologics, by Surgery Type USD Million (2021-2026)
  • Table 174. Italy Spine Biologics, by Type USD Million (2021-2026)
  • Table 175. Italy Spine Biologics, by Application USD Million (2021-2026)
  • Table 176. Italy Spine Biologics, by Surgery Type USD Million (2021-2026)
  • Table 177. United Kingdom Spine Biologics, by Type USD Million (2021-2026)
  • Table 178. United Kingdom Spine Biologics, by Application USD Million (2021-2026)
  • Table 179. United Kingdom Spine Biologics, by Surgery Type USD Million (2021-2026)
  • Table 180. Netherlands Spine Biologics, by Type USD Million (2021-2026)
  • Table 181. Netherlands Spine Biologics, by Application USD Million (2021-2026)
  • Table 182. Netherlands Spine Biologics, by Surgery Type USD Million (2021-2026)
  • Table 183. Rest of Europe Spine Biologics, by Type USD Million (2021-2026)
  • Table 184. Rest of Europe Spine Biologics, by Application USD Million (2021-2026)
  • Table 185. Rest of Europe Spine Biologics, by Surgery Type USD Million (2021-2026)
  • Table 186. MEA Spine Biologics, by Country USD Million (2021-2026)
  • Table 187. MEA Spine Biologics, by Type USD Million (2021-2026)
  • Table 188. MEA Spine Biologics, by Application USD Million (2021-2026)
  • Table 189. MEA Spine Biologics, by Surgery Type USD Million (2021-2026)
  • Table 190. Middle East Spine Biologics, by Type USD Million (2021-2026)
  • Table 191. Middle East Spine Biologics, by Application USD Million (2021-2026)
  • Table 192. Middle East Spine Biologics, by Surgery Type USD Million (2021-2026)
  • Table 193. Africa Spine Biologics, by Type USD Million (2021-2026)
  • Table 194. Africa Spine Biologics, by Application USD Million (2021-2026)
  • Table 195. Africa Spine Biologics, by Surgery Type USD Million (2021-2026)
  • Table 196. North America Spine Biologics, by Country USD Million (2021-2026)
  • Table 197. North America Spine Biologics, by Type USD Million (2021-2026)
  • Table 198. North America Spine Biologics, by Application USD Million (2021-2026)
  • Table 199. North America Spine Biologics, by Surgery Type USD Million (2021-2026)
  • Table 200. United States Spine Biologics, by Type USD Million (2021-2026)
  • Table 201. United States Spine Biologics, by Application USD Million (2021-2026)
  • Table 202. United States Spine Biologics, by Surgery Type USD Million (2021-2026)
  • Table 203. Canada Spine Biologics, by Type USD Million (2021-2026)
  • Table 204. Canada Spine Biologics, by Application USD Million (2021-2026)
  • Table 205. Canada Spine Biologics, by Surgery Type USD Million (2021-2026)
  • Table 206. Mexico Spine Biologics, by Type USD Million (2021-2026)
  • Table 207. Mexico Spine Biologics, by Application USD Million (2021-2026)
  • Table 208. Mexico Spine Biologics, by Surgery Type USD Million (2021-2026)
  • Table 209. Spine Biologics: by Type(USD/Units)
  • Table 210. Research Programs/Design for This Report
  • Table 211. Key Data Information from Secondary Sources
  • Table 212. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Spine Biologics: by Type USD Million (2015-2020)
  • Figure 5. Global Spine Biologics: by Application USD Million (2015-2020)
  • Figure 6. Global Spine Biologics: by Surgery Type USD Million (2015-2020)
  • Figure 7. South America Spine Biologics Share (%), by Country
  • Figure 8. Asia Pacific Spine Biologics Share (%), by Country
  • Figure 9. Europe Spine Biologics Share (%), by Country
  • Figure 10. MEA Spine Biologics Share (%), by Country
  • Figure 11. North America Spine Biologics Share (%), by Country
  • Figure 12. Global Spine Biologics: by Type USD/Units (2015-2020)
  • Figure 13. Global Spine Biologics share by Players 2020 (%)
  • Figure 14. Global Spine Biologics share by Players (Top 3) 2020(%)
  • Figure 15. Global Spine Biologics share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Zimmer Holding (United States) Revenue, Net Income and Gross profit
  • Figure 18. Zimmer Holding (United States) Revenue: by Geography 2020
  • Figure 19. Medical Devices Business Services, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 20. Medical Devices Business Services, Inc. (United States) Revenue: by Geography 2020
  • Figure 21. Medtronic (Ireland) Revenue, Net Income and Gross profit
  • Figure 22. Medtronic (Ireland) Revenue: by Geography 2020
  • Figure 23. NuVasive, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 24. NuVasive, Inc. (United States) Revenue: by Geography 2020
  • Figure 25. Stryker Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 26. Stryker Corporation (United States) Revenue: by Geography 2020
  • Figure 27. Orthofix International (United States) Revenue, Net Income and Gross profit
  • Figure 28. Orthofix International (United States) Revenue: by Geography 2020
  • Figure 29. Globus Medical (United States) Revenue, Net Income and Gross profit
  • Figure 30. Globus Medical (United States) Revenue: by Geography 2020
  • Figure 31. Exactech, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Exactech, Inc. (United States) Revenue: by Geography 2020
  • Figure 33. Wright Medical Group N.V. (United States) Revenue, Net Income and Gross profit
  • Figure 34. Wright Medical Group N.V. (United States) Revenue: by Geography 2020
  • Figure 35. NuTech (United States) Revenue, Net Income and Gross profit
  • Figure 36. NuTech (United States) Revenue: by Geography 2020
  • Figure 37. Arthrex, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 38. Arthrex, Inc. (United States) Revenue: by Geography 2020
  • Figure 39. Global Spine Biologics: by Type USD Million (2021-2026)
  • Figure 40. Global Spine Biologics: by Application USD Million (2021-2026)
  • Figure 41. Global Spine Biologics: by Surgery Type USD Million (2021-2026)
  • Figure 42. South America Spine Biologics Share (%), by Country
  • Figure 43. Asia Pacific Spine Biologics Share (%), by Country
  • Figure 44. Europe Spine Biologics Share (%), by Country
  • Figure 45. MEA Spine Biologics Share (%), by Country
  • Figure 46. North America Spine Biologics Share (%), by Country
  • Figure 47. Global Spine Biologics: by Type USD/Units (2021-2026)
List of companies from research coverage that are profiled in the study
  • Zimmer Holding (United States)
  • Medical Devices Business Services, Inc. (United States)
  • Medtronic (Ireland)
  • NuVasive, Inc. (United States)
  • Stryker Corporation (United States)
  • Orthofix International (United States)
  • Globus Medical (United States)
  • Exactech, Inc. (United States)
  • Wright Medical Group N.V. (United States)
  • NuTech (United States)
  • Arthrex, Inc. (United States)
Additional players considered in the study are as follows:
XTANT MEDICAL (United States) , ATEC Spine, Inc. (United States) , Life Spine, Inc. (United States)
Select User Access Type

Key Highlights of Report


Mar 2021 200 Pages 82 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Spine Biologics Quantitative research analysis
Global Spine Biologics Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Global Spine Biologics market is expected to see a growth of % during projected year 2020 to 2026.
The prominent players of Global Spine Biologics market are Zimmer Holding (United States), Medical Devices Business Services, Inc. (United States), Medtronic (Ireland), NuVasive, Inc. (United States), Stryker Corporation (United States), Orthofix International (United States), Globus Medical (United States), Exactech, Inc. (United States), Wright Medical Group N.V. (United States), NuTech (United States) and Arthrex, Inc. (United States), to name a few.
In this highly competitive & fast evolving Spine Biologics industry, the top strategic priorities would remain consistent like innovation, R&D and M&A.

Know More About Global Spine Biologics Report?

Have a Query? Click Here

Other Related Reports

Skilled Nursing Care Services Comprehensive Study by Type (Home Care, Residential Care, Acute Care), Application (Old Age People, Children), Connectivity (Connected To Hospital, Connected To Assisted...
$ 3650
Blood Bags Comprehensive Study by Type (Single Collection, Double Collection, Triple Collection, Quadruple Collection, Others.), Capacity Type (0 ml – 100 ml, 100 ml – 250 ml, 250 ml -450 ml, 450 ml ...
$ 3650
Breast Lesion Localization Methods Comprehensive Study by Type (Wire, Radioisotope, Electromagnetic, Magnetic, Other), Application (Women, Men), End-Users (Diagnostic Centers, Hospitals, Ambulatory S...
$ 3350
Microbial Identification Service Comprehensive Study by Type (Instruments {Automated Microbial Identification Systems,.Mass Spectrometers, PCR, Microarrays, High-power Microscopes, Polystainers, Flow...
$ 3750
Ultrasonic Toothbrush Comprehensive Study by Type (Single Frequency, Dual Frequency), Application (Therapeutic Medical Devices, Household, Others), Components (Circuit, Motor, Switch, Cam and gears, ...
$ 3450
Veterinary Reference Laboratory Comprehensive Study by Type (Clinical Chemistry Services, Immunodiagnostic Services, Hematology Services, Urinalysis Services, Molecular Diagnostic Services, Other (Mi...
$ 3750